“Retinitis Pigmentosa Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinitis Pigmentosa Market.
The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Retinitis Pigmentosa Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Retinitis Pigmentosa treatment therapies with a considerable amount of success over the years.
-
Retinitis Pigmentosa companies working in the treatment market are Biogen, Neurotech, Ionis Pharmaceuticals, Nacuity Pharmaceuticals, Allegro Ophthalmics, ID Pharma, Nightstar Therapeutics, Allegro Ophthalmics, Nacuity Pharmaceuticals, and others, are developing therapies for the Retinitis Pigmentosa treatment
-
Emerging Retinitis Pigmentosa therapies in the different phases of clinical trials are- AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, BIIB-112, QR 1123 (formerly ISIS RHO 2.5Rx), AAV8-RPGR, Risuteganib, NPI 001, and others are expected to have a significant impact on the Retinitis Pigmentosa market in the coming years.
-
In April 2024, Ocugen announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to begin a Phase III clinical trial of OCU400, a gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP).
-
In April 2024, ViGeneron announced that the first patient has received a dose in its Phase Ib clinical trial, which is evaluating the intravitreal injection of VG901 for the treatment of retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene.
-
In March 2024, Nanoscope Therapeutics revealed positive top-line results following the completion of its 2-year Phase IIb RESTORE randomized, controlled clinical trial. The trial evaluated MCO-010, a mutation-agnostic gene therapy, for patients experiencing permanent and severe vision loss due to advanced retinitis pigmentosa (RP).
-
In February 2024, jCyte announced a successful outcome from its pre-phase III Type B meeting with the US Food and Drug Administration (FDA) on January 16, 2024. The company is also preparing to launch its pivotal US trial for jCell in the second half of 2024.
Retinitis Pigmentosa Overview
Retinitis Pigmentosa (RP) encompasses a collection of hereditary retinal conditions responsible for retinal degeneration and eventual vision loss. This disorder is identified by the gradual deterioration of both rod and cone photoreceptors in the retina, resulting in symptoms such as night blindness and the progressive development of visual field impairments.
Get a Free Sample PDF Report to know more about Retinitis Pigmentosa Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/retinitis-pigmentosa-retinitis-pipeline-insight
Emerging Retinitis Pigmentosa Drugs Under Different Phases of Clinical Development Include:
-
AAV2/5-RPGR: Biogen
-
CPK850: Neurotech
-
Ophthalmic examinations: Ionis Pharmaceuticals:
-
Mobility Test: Nacuity Pharmaceuticals
-
NT-501: Allegro Ophthalmics
-
RST-001: ID Pharma
-
BIIB-112: Biogen
-
QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
-
AAV8-RPGR: Nightstar Therapeutics/Biogen
-
Risuteganib: Allegro Ophthalmics
-
NPI 001: Nacuity Pharmaceuticals
Retinitis Pigmentosa Route of Administration
Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Retinitis Pigmentosa Molecule Type
Retinitis Pigmentosa Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Retinitis Pigmentosa Pipeline Therapeutics Assessment
-
Retinitis Pigmentosa Assessment by Product Type
-
Retinitis Pigmentosa By Stage and Product Type
-
Retinitis Pigmentosa Assessment by Route of Administration
-
Retinitis Pigmentosa By Stage and Route of Administration
-
Retinitis Pigmentosa Assessment by Molecule Type
-
Retinitis Pigmentosa by Stage and Molecule Type
DelveInsight's Retinitis Pigmentosa Report covers around 45+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Retinitis Pigmentosa product details are provided in the report. Download the Retinitis Pigmentosa pipeline report to learn more about the emerging Retinitis Pigmentosa therapies
Some of the key companies in the Retinitis Pigmentosa Therapeutics Market include:
Key companies developing therapies for Retinitis Pigmentosa are - Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, M's Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics, Sun Pharma Advanced Research Company, and others.
Retinitis Pigmentosa Pipeline Analysis:
The Retinitis Pigmentosa pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
-
Retinitis Pigmentosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Retinitis Pigmentosa drugs and therapies
Retinitis Pigmentosa Pipeline Market Drivers
-
Increasing Prevalence, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Retinitis Pigmentosa Market.
Retinitis Pigmentosa Pipeline Market Barriers
-
However, side-effects associated with the treatment of Retinitis Pigmentosa, limited treatment options for retinitis Pigmentosa and other factors are creating obstacles in the Retinitis Pigmentosa Market growth.
Scope of Retinitis Pigmentosa Pipeline Drug Insight
-
Coverage: Global
-
Key Retinitis Pigmentosa Companies: Biogen, Neurotech, Ionis Pharmaceuticals, Nacuity Pharmaceuticals, Allegro Ophthalmics, ID Pharma, Nightstar Therapeutics, Allegro Ophthalmics, Nacuity Pharmaceuticals, and others
-
Key Retinitis Pigmentosa Therapies: AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, BIIB-112, QR 1123 (formerly ISIS RHO 2.5Rx), AAV8-RPGR, Risuteganib, NPI 001, and others
-
Retinitis Pigmentosa Therapeutic Assessment: Retinitis Pigmentosa current marketed and Retinitis Pigmentosa emerging therapies
-
Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa market drivers and Retinitis Pigmentosa market barriers
Request for Sample PDF Report for Retinitis Pigmentosa Pipeline Assessment and clinical trials
Table of Contents
1. Retinitis Pigmentosa Report Introduction
2. Retinitis Pigmentosa Executive Summary
3. Retinitis Pigmentosa Overview
4. Retinitis Pigmentosa- Analytical Perspective In-depth Commercial Assessment
5. Retinitis Pigmentosa Pipeline Therapeutics
6. Retinitis Pigmentosa Late Stage Products (Phase II/III)
7. Retinitis Pigmentosa Mid Stage Products (Phase II)
8. Retinitis Pigmentosa Early Stage Products (Phase I)
9. Retinitis Pigmentosa Preclinical Stage Products
10. Retinitis Pigmentosa Therapeutics Assessment
11. Retinitis Pigmentosa Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Retinitis Pigmentosa Key Companies
14. Retinitis Pigmentosa Key Products
15. Retinitis Pigmentosa Unmet Needs
16 . Retinitis Pigmentosa Market Drivers and Barriers
17. Retinitis Pigmentosa Future Perspectives and Conclusion
18. Retinitis Pigmentosa Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
